Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis

Imagem de Miniatura
Arquivos
art_BEZERRA-SOUZA_Nanoemulsified_Butenafine_for_Enhanced_Performance_against_Experimental_Cutaneous_2021.PDF (5.04 MB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI LTD
Autores
LALATSA, Aikaterini
SERRANO, Dolores R.
PASSERO, Luiz Felipe D.
Citação
JOURNAL OF IMMUNOLOGY RESEARCH, v.2021, article ID 8828750, 13p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The production of ergosterol lipid involves the activity of different enzymes and is a crucial event for the Leishmania membrane homeostasis. Such enzymes can be blocked by azoles and allylamines drugs, such as the antifungal butenafine chloride. This drug was active on parasites that cause cutaneous and visceral leishmaniasis. Based on the leishmanicidal activity of butenafine chloride and considering the absence of reports about the therapeutic potential of this drug in cutaneous leishmaniasis, the present work is aimed at analyzing the efficacy of butenafine formulated in two different topical delivery systems, the self-nanoemulsifying drug delivery systems (BUT-SNEDDS) and in a SNEDDS-based nanogel (BUT-SNEDDS gel) as well as in the free form in experimental cutaneous leishmaniasis. Physical studies showed that both formulations were below 300 nm with low polydispersity (<0.5) and good colloidal stability (around -25 mV). Increased steady-state flux was reported for nanoenabled butenafine formulations with reduced lag time in Franz cell diffusion assays across Strat-M membranes. No toxic or inflammatory reactions were detected in animals treated with BUT-SNEDDS, BUT-SNEDDS gel, or butenafine. Animals topically treated with butenafine (free or nanoformulated) showed small dermal lesions and low tissue parasitism. Furthermore, BUT-SNEDD gel and butenafine presented similar efficacy than the standard drug Glucantime given by the intralesional route. Increased levels of IFN-gamma were observed in animals treated with BUT-SNEDDS gel or butenafine. Based on these data, the antifungal drug butenafine chloride can be considered an interesting repurposed drug for the treatment of cutaneous leishmaniasis.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/40858
Referências
  1. Bahamdan KA, 1997, INT J DERMATOL, V36, P59, DOI 10.1046/j.1365-4362.1997.00021.x
  2. Bezerra-Souza A, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070353
  3. Bezerra-Souza A, 2016, PARASITOL INT, V65, P702, DOI 10.1016/j.parint.2016.08.003
  4. Bordon MLAC, 2018, J VENOM ANIM TOXINS, V24, DOI 10.1186/s40409-018-0156-9
  5. Braga SS, 2019, EUR J MED CHEM, V183, DOI 10.1016/j.ejmech.2019.111660
  6. Brasileiro A, 2017, J EUR ACAD DERMATOL, V31, pE59, DOI 10.1111/jdv.13726
  7. Campos BLS, 2015, PARASITE IMMUNOL, V37, P407, DOI 10.1111/pim.12206
  8. Carvalho SH, 2019, TROP MED INT HEALTH, V24, P380, DOI 10.1111/tmi.13210
  9. Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
  10. Cordoba S, 2012, ALLERGY, V67, P1609, DOI 10.1111/all.12050
  11. Silva STD, 2018, J ANTIMICROB CHEMOTH, V73, P2360, DOI 10.1093/jac/dky229
  12. Passero LFD, 2018, CURR TOP MED CHEM, V18, P1275, DOI 10.2174/1568026618666181002114448
  13. Passero LFD, 2010, APMIS, V118, P973, DOI 10.1111/j.1600-0463.2010.02679.x
  14. Farajzadeh Saeedeh, 2016, J Parasit Dis, V40, P1159, DOI 10.1007/s12639-014-0641-1
  15. Fernandez-Garcia R, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118817
  16. Frezard F, 2009, MOLECULES, V14, P2317, DOI 10.3390/molecules14072317
  17. Ganeshpurkar A, 2014, INDIAN J DERMATOL, V59, P369, DOI 10.4103/0019-5154.135489
  18. GOAD LJ, 1989, MOL BIOCHEM PARASIT, V32, P179, DOI 10.1016/0166-6851(89)90069-8
  19. Haldar Arun Kumar, 2011, Mol Biol Int, V2011, P571242, DOI 10.4061/2011/571242
  20. HART DT, 1989, MOL BIOCHEM PARASIT, V33, P123, DOI 10.1016/0166-6851(89)90026-1
  21. Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608
  22. Lalatsa A, 2012, MOL PHARMACEUT, V9, P1764, DOI 10.1021/mp300068j
  23. Lalatsa A, 2020, INT J PHARMACEUT, V577, DOI 10.1016/j.ijpharm.2019.119003
  24. Lalatsa A, 2016, BRIT J OPHTHALMOL, V100, P871, DOI 10.1136/bjophthalmol-2015-308250
  25. Lana RS, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/385493
  26. Laurenti MD, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/134236
  27. Lemke A, 2005, APPL MICROBIOL BIOT, V68, P151, DOI 10.1007/s00253-005-1955-9
  28. Lepesheva GI, 2018, PARASITOLOGY, V145, P1820, DOI 10.1017/S0031182018000562
  29. Lopez L, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006653
  30. Neva FA, 1997, T ROY SOC TROP MED H, V91, P473, DOI 10.1016/S0035-9203(97)90290-X
  31. Okwor I, 2008, IMMUNOL RES, V41, P123, DOI 10.1007/s12026-008-8016-2
  32. Passero LFD, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-64
  33. Purkait B, 2012, ANTIMICROB AGENTS CH, V56, P1031, DOI 10.1128/AAC.00030-11
  34. Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
  35. Rojas R, 2006, J INFECT DIS, V193, P1375, DOI 10.1086/503371
  36. Ryder N.S., 1990, BIOCH CELL WALLS MEM, P189
  37. Serrano DR, 2017, J DRUG DELIV SCI TEC, V42, P75, DOI 10.1016/j.jddst.2017.04.017
  38. Serrano DR, 2015, MOL PHARMACEUT, V12, P420, DOI 10.1021/mp500527x
  39. Serrano-Martin X, 2009, ANTIMICROB AGENTS CH, V53, P1403, DOI 10.1128/AAC.01215-08
  40. Shekhova E, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00978-17, 10.1128/aac.00978-17]
  41. Silva EJG, 2018, FUTURE MED CHEM, V10, P2069, DOI 10.4155/fmc-2018-0124
  42. Smith L, 2018, MOL PHARMACEUT, V15, P2570, DOI 10.1021/acs.molpharmaceut.8b00097
  43. Sosa N, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007253
  44. Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x
  45. Sundar S, 2018, PARASITOLOGY, V145, P481, DOI 10.1017/S0031182017002116
  46. Sundar S, 2012, CLIN INFECT DIS, V55, P543, DOI 10.1093/cid/cis474
  47. Trinconi CT, 2018, PARASITOLOGY, V145, P490, DOI 10.1017/S0031182017000130
  48. VANNIERSANTOS MA, 1995, J EUKARYOT MICROBIOL, V42, P337, DOI 10.1111/j.1550-7408.1995.tb01591.x
  49. Yamamoto ES, 2020, BIOORG CHEM, V102, DOI 10.1016/j.bioorg.2020.104056
  50. Yamamoto ES, 2018, CURR TOP MED CHEM, V18, P2338, DOI 10.2174/1568026619666181220114627
  51. Yamamoto ES, 2014, PARASITOL RES, V113, P333, DOI 10.1007/s00436-013-3659-x
  52. Zakai HA, 2000, ANN TROP MED PARASIT, V94, P787, DOI 10.1080/00034980020027979
  53. Zakai Haytham A., 2003, Journal of the Egyptian Society of Parasitology, V33, P97

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - LIM/50